Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
ACMG Response to Opposing Inclusion of the VALID Act in the FDASLA Act
-
Group Sign-on Letter Concerning the VALID Act of 2022 Discussion Draft
-
Sign-on Letter Concerning Patent Legislation Negotiation Process
-
ACMG Response to RFI on NIH Genomic Data Sharing Policy
-
Group Sign-On Letter Urging CLIAC to Discuss CLIA Modernization
-
Group Sign-On Letter Supporting the VITAL Act
-
Group Letter to Biden Administration Regarding Patent Eligibility Reform
-
Group Sign-on Letter to Congress Expressing Concerns about Patent Eligibility Reform Stakeholder Discussions
-
ACMG Letter to Congress Concerning the Verifying Accurate Leading-edge IVCT Development (VALID) Act